Action ASLN ASLAN PHARMACEUTICALS LIMITED
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues ASLAN Pharmaceuticals Limited

Actions

ASLN

US04522R2004

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 26/04/2024 		Varia. 5j. Varia. 1 janv.
0,4153 USD -7,30% Graphique intraday de ASLAN Pharmaceuticals Limited -18,89% -20,46%
26/04 Les actions asiatiques négociées aux États-Unis sous forme de certificats de dépôt américains sont en hausse vendredi et terminent la semaine en hausse de 3,5%. MT
25/04 Les valeurs technologiques en tête des actions asiatiques échangées aux Etats-Unis en tant que American Depositary Receipts en baisse dans les échanges de jeudi MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Asian Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading, End Week Up 3.5%
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Lower in Thursday Trading
ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice - April 19, 2024
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
ASLAN PHARMACEUTICALS : ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS - Form 6-K
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
ASLAN PHARMACEUTICALS : ANNOUNCES RECEIPT OF NASDAQ NOTICE - Form 6-K
Asian Equities Traded in the US as American Depositary Receipts Fall Again in Friday Trading
Asian Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading
Asian Equities Traded in the US as American Depositary Receipts Remain Flat in Wednesday Trading
Financial, Telecoms Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Sharply Lower Tuesday
Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and provides corporate update
Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading
ASLAN Pharmaceuticals : AMENDMENT NO. 2 TO THE OPEN MARKET SALE AGREEMENTSM - Form 6-K
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ASLN
  4. Actualités ASLAN Pharmaceuticals Limited
  5. Autres langues